Pharmaceutical News

RSS

Arte, ProJect Pharmaceutics partner to develop Lyo-DCPS

Arte Corporation and ProJect Pharmaceutics have been working closely on the development of a new type of dual chamber prefillable syringe for freeze-dried pharmaceuticals. The two companies have joined together with the objective to provide innovative dual chamber syringes for the global pharmaceutical market.

6 Jun 2012

FDA issues complete response letter to Merck’s ridaforolimus NDA

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for ridaforolimus.

6 Jun 2012

BioLineRx receives two U.S. patent allowances for BL-1021 to treat neuropathic pain

BioLineRx, a biopharmaceutical development company, announced today that two Notices of Allowance have been issued by the United States Patent and Trademark Office (USPTO) for BL-1021, an orally available small molecule for treating neuropathic pain.

6 Jun 2012

BioInvent, ThromboGenics to regain global rights to TB-403 from Roche

ThromboGenics NV and co-development partner BioInvent International announce today that they will regain global rights to TB-403 from Roche.

6 Jun 2012

FDA approves Lupin’s SUPRAX capsules

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. has received approval for SUPRAX (Cefixime) Capsules 400 mg from the United States Food and Drugs Administration (FDA).

6 Jun 2012

Family members of children with staph infections often harbor drug-resistant germs

Family members of children with a staph infection often harbor a drug-resistant form of the germ, although they don't show symptoms, a team of researchers from Washington University School of Medicine in St. Louis has found.

5 Jun 2012

Investigational diabetes drug appears to improve insulin sensitivity without side effects

Drugs for type 2 diabetes can contribute to weight gain, bone fractures and cardiovascular problems, but in mice, an investigational drug appears to improve insulin sensitivity without those troublesome side effects, researchers at Washington University School of Medicine in St. Louis have shown.

5 Jun 2012

ASS234 molecule inhibits aggregation of the Alzheimer's protein

Researchers at Universitat Aut-noma de Barcelona (UAB), the Spanish National Research Council (CSIC) and the University of Barcelona (UB) have developed a multitarget molecule, ASS234, which according to the results of in vitro studies conducted, inhibits the aggregation of the --amyloid protein, involved in Alzheimer's disease.

5 Jun 2012

Androgen receptor an additional hormonal target in many breast cancers

Many breast cancers depend on hormones including estrogen or progesterone for their survival and proliferation. Eight years of lab work at the University of Colorado Cancer Center and elsewhere suggest that the androgen (AR) receptor is an additional hormonal target in many breast cancers. Block AR+ breast cancer's ability to access androgen and you block the cancer's ability to survive.

5 Jun 2012

Nouveau Life launches new weight loss supplement

Nouveau Life Pharmaceuticals Inc., a leading provider of quality all-natural dietary supplements, announced today the release of its newest supplement product: New Life Naturals: For Your Weight Loss.

5 Jun 2012

ProStrakan, Orexo reconfigure commercial rights to Abstral

Orexo AB and ProStrakan Group plc jointly announce today that the companies have reconfigured the commercial rights to the product, Abstral, in various territories worldwide.

4 Jun 2012

Prisoners need education on the appropriate use of topical antibiotic products

Prisoners need education on the appropriate use of topical antibiotic products, according to a study released today at the 39th Annual Educational Conference and International Meeting of the Association for Professionals in Infection Control and Epidemiology.

4 Jun 2012

CTI acquires world-wide rights to S*BIO’s pacritinib

Cell Therapeutics, Inc., announced today that it has completed its acquisition gaining world-wide rights to S*BIO Pte Ltd.'s pacritinib.

4 Jun 2012

New research: Foggers ineffective against bed bugs

Consumer products known as "bug bombs" or "foggers" have been sold for decades for use against many common household insects. However, recent research published in the Journal of Economic Entomology (JEE) shows these products to be ineffective against bed bugs.

4 Jun 2012

Reumofan Plus may have harmful pharmaceutical ingredients, warns FDA

The U.S. Food and Drug Administration is warning consumers that Reumofan Plus, marketed as a "natural" dietary supplement for pain relief and other serious conditions, contains several active pharmaceutical ingredients not listed on the label that could be harmful.

2 Jun 2012

Global generic pharmaceuticals market to reach $231.00 billion in 2017 at 9.29% CAGR

The global generic pharmaceuticals market is likely to witness strong growth in the next few years owing to the patent expiration of key blockbuster drugs and the judicious cost containment efforts of governments and healthcare service providers worldwide.

2 Jun 2012

Cera announces new citrus ready-to-drink oral rehydration solution

Cera Products is proud to announce its new CeraLyte-70 Citrus Ready to Drink in a 500 ml environmentally green container with a re-closeable top and a long shelf-life. No mixing is needed, saving health care staff time when fast patient hydration is needed.

2 Jun 2012

Cardinal Health to produce new AD diagnostic imaging agent, Amyvid

Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.

2 Jun 2012

Pisgah receives USPTO Notice of Allowance for drug abuse solution

Pisgah Laboratories, Inc. received Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled "Opioid Salts and Formulations Exhibiting Anti-Abuse and Anti-Dose Dumping Properties."

2 Jun 2012

HIV markets in rich, poor countries are two distinct markets

HIV drugs have not only "transformed a fatal disease into a chronic one," but "[t]hey have also made HIV a big business," this Economist editorial states.

2 Jun 2012